RE:RE:RE:RE:RE:RE:Are we halted ?This reasoning is in the context of a belief (which I strongly expressed at the time of the Clinical Protocol) that on the basis of the preclinical evidence TLD-1433 deserved to be trialled as a first-line treatment against early stage disease. Many lesser prospects had and have been permitted this setting.